Outpatient Protocol for Managing Acute Canine Pancreatitis Using a Novel Wearable Pain Device

Cost

Free for Elite Members

September 2025

In today’s VETgirl online veterinary continuing education podcast, we’re diving into a hot topic: managing pancreatitis in dogs. More specifically, we’re taking a closer look at an outpatient treatment protocol. Let’s face it, treatment for pancreatitis can be prolonged and expensive, often requiring hospitalization, intravenous (IV) fluids, antiemetic therapy, nutritional support, analgesics, anti-inflammatory therapy, and 24/7 care, and that’s not always possible for some clients and patients. But what if there were a practical, cost-conscious alternative that could be managed outside the hospital for the more mild to moderate cases that strikes a balance between effective clinical care and financial feasibility for clients?

Resource:

Erger C, Mauro KD, Mendoza-White I, et al. Successful outpatient pain management in dogs with mild to moderate pancreatitis using a novel wearable device for continuous hydromorphone delivery. J Vet Inter Med 2025;39:e70217.

Ceva logo

Today’s VETgirl podcast is sponsored by CEVA Animal Health, makers of PANOQUELL®- CA1 (fuzapladib sodium for injection). PANOQUELL®- CA1 is the first and only conditionally approved innovative solution for the management of the clinical signs associated with acute onset of canine pancreatitis. For more information, go to https://www.panoquell.com/.

PANOQUELL®-CA1 is conditionally approved by FDA pending full demonstration of effectiveness under application number 141‑567. Based on the data submitted by the sponsor for the conditional approval, FDA determined that the drug is safe and has a reasonable expectation of effectiveness when used according to the labeling. It is a violation of Federal law to use this product other than as directed in the labeling.

IMPORTANT SAFETY INFORMATION: The safe use of PANOQUELL®‑CA1 has not been evaluated in dogs with cardiac disease, hepatic failure, renal impairment, dogs that are pregnant, lactating, intended for breeding or puppies under 6 months of age. PANOQUELL®‑CA1 should not be used in dogs with a known hypersensitivity to fuzapladib sodium. PANOQUELL®‑CA1 is a highly protein bound drug and its use with other highly protein bound medications have not been studied. The most common side effects in the pilot field study were anorexia, digestive tract disorders, respiratory tract disorders and jaundice. PANOQUELL®‑CA1 is not for use in humans. Limited data is available on the potential teratogenic effects of fuzapladib sodium. Therefore, anyone who is pregnant, breast feeding or planning to become pregnant should avoid direct contact with PANOQUELL®‑CA1. For additional information on the use of PANOQUELL®‑CA1, please refer to the product insert.

Please note that the opinions in this podcast are expressed by the speaker/sponsor, and not directly endorsed by VETgirl.

Not a VETgirl ELITE member? Get your learning on with the #1 veterinary CE resource – clinically relevant, practical, and accessible 24/7 on your own time! Don’t miss out – click HERE to check out your options, including our new  14-day, no-commitment ELITE Trial.

Only VETgirl members can leave comments. Sign In or Join VETgirl now!